Literature DB >> 11457579

Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system.

D Braida1, M Pozzi, R Cavallini, M Sala.   

Abstract

Cannabinoids appear atypical as drugs of abuse since controversial data exist concerning the ability to lower the thresholds for electrical self-stimulation (Stark and Dews, 1980; Gardner et al., 1988; Gardner, 1992) and to support self-administration (Martellotta et al., 1998; Tanda et al., 2000) or conditioned place preference in animals (Lepore et al., 1995; Parker and Gillies, 1995; McGregor et al., 1996; Sañudo-Peña et al., 1997; Chaperon et al., 1998; Hutcheson et al., 1998; Mallet and Beninger, 1998; Cheer et al., 2000; Valjent and Maldonado, 2000). Opioids and cannabinoids share some pharmacological properties (Manzanares et al., 1999). The most interactions were found in antinociception (Welch and Stevens, 1992; Smith et al., 1994) and, to a lesser extent, in drug reinforcement (Chen et al., 1990; Vela et al., 1995; Tanda et al., 1997). In the present study we asked whether: (1) a potent synthetic cannabinoid receptor agonist, [(-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptil)-phenyl]-trans-4-(3-hydroxy propyl) cyclohexanol] (CP 55,940) (from 10 to 40 microg/kg), which binds to the brain cannabinoid receptors with high affinity (Herkenham et al., 1991), would induce conditioned place preference, in comparison with heroin (from 0.1 to 5 mg/kg); (2) what type of receptor was involved; (3) what kind of interaction there was between the two drugs, when given in combination, on reward. CP 55,940 elicited a conditioned place preference only at a dose of 20 microg/kg similar in intensity to that of heroin (2 mg/kg). The reinforcing properties of the cannabinoid agonist were fully antagonised by pretreatment with the brain cannabinoid receptor-1 (CB(1)) antagonist, [N-piperidino-5-(4-chlorophenyl) 1-(2,4-dichloro-phenyl)-4-methyl pyrazole-3-carboxamide hydrochloride] (SR 141716A) and naloxone. The combination of CP 55,940 and heroin, at the reinforcing doses, led to a reward which did not show any additive effect. Taken together these findings are important for understanding how the cannabinoids produce reward and the interconnection of the opioid and cannabinoid system in the motivation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11457579     DOI: 10.1016/s0306-4522(01)00210-x

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  43 in total

1.  Role of the endocannabinoid system in MDMA intracerebral self-administration in rats.

Authors:  Daniela Braida; Mariaelvina Sala
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

2.  Role of different brain structures in the behavioural expression of WIN 55,212-2 withdrawal in mice.

Authors:  Anna Castañé; Rafael Maldonado; Olga Valverde
Journal:  Br J Pharmacol       Date:  2004-07-20       Impact factor: 8.739

3.  Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential.

Authors:  Sherrica Tai; William E Fantegrossi
Journal:  Curr Addict Rep       Date:  2014-06-01

4.  Selective breeding for high alcohol preference is associated with increased sensitivity to cannabinoid reward within the nucleus accumbens shell.

Authors:  Sheketha R Hauser; Simon N Katner; Robert A Waeiss; William A Truitt; Richard L Bell; William J McBride; Zachary A Rodd
Journal:  Pharmacol Biochem Behav       Date:  2020-07-23       Impact factor: 3.533

5.  Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward.

Authors:  David J Rademacher; Cecilia J Hillard
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-12-28       Impact factor: 5.067

Review 6.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

7.  Additive antinociceptive effects of mixtures of the κ-opioid receptor agonist spiradoline and the cannabinoid receptor agonist CP55940 in rats.

Authors:  David R Maguire; Charles P France
Journal:  Behav Pharmacol       Date:  2016-02       Impact factor: 2.293

8.  CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat.

Authors:  M Sabrina Spano; Liana Fattore; Gregorio Cossu; Serena Deiana; Paola Fadda; Walter Fratta
Journal:  Br J Pharmacol       Date:  2004-08-31       Impact factor: 8.739

9.  The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys.

Authors:  Zuzana Justinova; Gianluigi Tanda; Patrik Munzar; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

10.  Effect of the CB1 cannabinoid agonist WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference in mice.

Authors:  Carmen Manzanedo; Marta Rodríguez-Arias; Manuel Daza-Losada; Concepción Maldonado; María A Aguilar; José Miñarro
Journal:  Behav Brain Funct       Date:  2010-03-22       Impact factor: 3.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.